XORTX Therapeutics Inc
XRTX0.400USD
-0.002-0.40%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
2.09MCap. mercado
PérdidaP/E TTM
Más Datos de XORTX Therapeutics Inc Compañía
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Información de XORTX Therapeutics Inc
Símbolo de cotizaciónXRTX
Nombre de la empresaXORTX Therapeutics Inc
Fecha de salida a bolsaSep 30, 2015
Director ejecutivoDavidoff (Allen W)
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 30
Dirección3710 - 33rd Street NW
CiudadCALGARY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalT2L 2M1
Teléfono14034557727
Sitio Webhttps://www.xortx.com/
Símbolo de cotizaciónXRTX
Fecha de salida a bolsaSep 30, 2015
Director ejecutivoDavidoff (Allen W)
Ejecutivos de XORTX Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: vie., 6 de feb
Actualizado: vie., 6 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
Baader Bank AG
0.27%
XTX Markets LLC
0.20%
Otro
88.34%
Accionistas
Accionistas
Proporción
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
Baader Bank AG
0.27%
XTX Markets LLC
0.20%
Otro
88.34%
Tipos de accionistas
Accionistas
Proporción
Corporation
8.22%
Individual Investor
1.91%
Hedge Fund
1.24%
Investment Advisor/Hedge Fund
0.27%
Venture Capital
0.20%
Investment Advisor
0.03%
Otro
88.13%
Participación institucional
Actualizado: mié., 21 de ene
Actualizado: mié., 21 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q4
10
101.02K
4.75%
--
2025Q4
16
102.18K
1.47%
-649.58K
2025Q3
16
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Lincoln Alternative Strategies LLC
572.47K
8.22%
+572.47K
--
Oct 23, 2025
Davidoff, Allen Warren
120.45K
1.73%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
86.33K
1.24%
+47.86K
+124.41%
Sep 30, 2025
XTX Markets LLC
13.82K
0.2%
+13.82K
--
Sep 30, 2025
Giovinazzo (Anthony)
9.63K
0.14%
--
--
Apr 30, 2025
UBS Financial Services, Inc.
234.00
0%
-20.56K
-98.87%
Sep 30, 2025
RBC Dominion Securities, Inc.
358.00
0.01%
-305.00
-46.00%
Sep 30, 2025
Van Damme (Paul Joseph)
324.00
0%
-6.79K
-95.44%
Oct 17, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
